Bovine milk exosomes for delivering vitamin d
Loading vitamin D2 and/or D3 onto bovine milk exosomes via mixing and freezing/thawing processes enhances their bioavailability, addressing the absorption challenges of fat-soluble vitamins and providing an effective supplementation method.
Patent Information
- Application Number
- PCT/US2024/031647
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
The bioavailability of fat-soluble vitamins, such as vitamin D, is limited due to inefficient absorption and transport mechanisms, leading to insufficient levels in the body, especially with limited dietary sources and sun exposure.
Bovine milk exosomes are loaded with vitamin D2 and/or D3 through a mixing and freezing/thawing process, creating a nutritional composition that enhances the bioavailability of these vitamins by using them as carriers for improved absorption.
The vitamin D-loaded bovine milk exosomes significantly increase the bioavailability of vitamin D2 and/or D3, providing a convenient and effective means to supplement vitamin D levels, as demonstrated by high loading efficiency and improved absorption compared to traditional methods.
Smart Images

Figure IMGF000023_0001 
Figure IMGF000024_0001
Abstract
Description
BOVINE MILK EXOSOMES FOR DELIVERING VITAMIN DFIELD OF THE INVENTION
[0001] The present invention relates to bovine milk exosomes loaded with vitamin D, nutritional compositions including bovine milk exosomes loaded with vitamin D, as well as methods of manufacturing bovine milk exosomes loaded with vitamin D, and methods of preparing nutritional compositions for providing improved bioavailability of vitamin D, or specifically, vitamin D2 and / or vitamin D3.BACKGROUND OF THE INVENTION
[0002] Vitamins are micronutrients. They are essential in even minute amounts (for example, less than 1 g / day) to facilitate normal development, growth and overall functioning of the human body. Vitamins are organic compounds that generally cannot be endogenously synthesized, and certainly cannot be endogenously synthesized in adequate amounts. Therefore, vitamins must be obtained from diet or supplements.
[0003] Vitamins can be divided into two general classes: water-soluble vitamins and fatsoluble vitamins. Fat-soluble vitamins include four groups of vitamin compounds (Vitamins A, D, E and K). These fat-soluble vitamins are also lipids. As such, these vitamins share commonalities between their fate in the gastrointestinal (Gl) tract during digestion, and their absorption by cells in the intestinal lining (enterocytes).
[0004] The bioavailability of fat-soluble vitamins can be determined by the relative amount of a vitamin molecule (or of one of its metabolites) that reaches systemic circulation or its site of action. This bioavailability depends on several successive steps. Namely, the vitamins need to be transferred from food or supplement to a location at which the vitamins are ingested, and then to tissues, where vitamin concentration is measured.
[0005] First, vitamin compounds are extracted from food or supplements and are transferred to mixed micelles - in other words, the vitamin compounds undergo micellization. Traditionally, the success of the micellization step is only partial, resulting in only a fraction of fat-soluble vitamins becoming available for absorption into tissues. This fraction is referred to as the bioaccessible fraction. Second, an uptake of the vitamin compounds (or their metabolites) produced during digestion occurs by an enterocyte. The vitamin compounds are then resecreted into the intestinal lumen.
[0006] Fat soluble vitamins are absorbed from the intestinal lumen using the same mechanisms used for absorption of other lipids. In short, fat soluble vitamins are incorporated into mixed micelles with other lipids and bile acids in the lumen of the small intestine and enter the enterocyte largely by diffusion. Within the enterocyte, fat soluble vitamins are incorporated into chylomicrons and exported via exocytosis into lymph fluid following their uptake, metabolism, and secretion into the blood stream by the liver. Blood metabolisms of different fatsoluble vitamins will usually differ. This is because some compounds, such as vitamin E and carotenoids, are transported in lipoproteins, while others are transported by other specific proteins.
[0007] Vitamin D has been known to aid absorption of calcium, magnesium, and phosphorus in an organism. However, this fat-soluble vitamin is traditionally present in insufficient quantities in the body often due to limited sun exposure, as two forms of vitamin D, vitamin D2 and vitamin D3, are produced in the presence of UV rays. Few food or beverage items contain vitamin D, so historically, vitamin D supplements have been provided to increase vitamin D quantities in the body.
[0008] In view of the above, there is an urgent need to develop new and accessible technologies that can conveniently provide an adequate and / or increased amount of vitamin D in vivo in human and animal subjects, for example, supplied by a nutritional composition.
[0009] Accordingly, a nutritional composition having bioavailable vitamin D and a method of making the nutritional composition are desirable.SUMMARY OF THE INVENTION
[0010] It is therefore an object of the invention to provide a convenient means for administering vitamin D in vivo.
[0011] In one embodiment, the invention is directed to bovine milk exosomes loaded with vitamin D.
[0012] In another embodiment, the invention is directed to a nutritional composition comprising at least one of protein, fat and carbohydrate, and further comprising the vitamin D- loaded bovine milk exosomes.
[0013] In another embodiment, the invention includes a method for manufacturing vitamin D- loaded bovine milk exosomes, comprising mixing an aqueous solution of bovine milk exosomes with at least one solubilized vitamin D.
[0014] A further embodiment of the invention is directed to a method for manufacturing the vitamin D-loaded bovine milk exosomes, comprising mixing an aqueous solution of bovine milk exosomes with at least one solubilized vitamin D and subjecting a resulting mixture to at least one freezing / thawing cycle.
[0015] Another embodiment of the invention includes a method of preparing a nutritional composition for providing improved bioavailability of vitamin D, or specifically, vitamin D2 and / or vitamin D3, in vivo. The method comprises adding bovine milk exosomes loaded with vitamin D, or specifically, vitamin D2 and / or vitamin D3, to a nutritional composition. The nutritional composition comprises at least one of, and in some cases all three of, protein, fat and carbohydrate.
[0016] The vitamin D-loaded exosomes, nutritional compositions and methods provide a convenient manner for supplying vitamin D and for increasing bioavailability of vitamin D, orspecifically , vitamin D2 and / or vitamin D3, in vivo. These and additional objects and advantages of the invention will be more fully apparent in view of the following detailed description.DETAILED DESCRIPTION
[0017] Specific embodiments of the invention are described herein. The invention can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided to illustrate more specific features of certain embodiments of the invention to those skilled in the art.
[0018] The terminology as set forth herein is for description of the embodiments only and should not be construed as limiting the disclosure as a whole. All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic or limitation, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made. Unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably. Furthermore, as used in the description and the appended claims, the singular forms “a,” “an,” and “the” are inclusive of their plural forms, unless the context clearly indicates otherwise.
[0019] To the extent that the term “includes” or “including” is used in the description or the claims, it is intended to be inclusive of additional elements or steps, in a manner similar to the term “comprising” as that term is interpreted when employed as a transitional word in a claim. Furthermore, to the extent that the term “or” is employed (e.g., A or B), it is intended to mean “A or B or both.” When the “only A or B but not both” is intended, then the term “only A or B but not both” is employed. Thus, use of the term “or” herein is the inclusive, and not the exclusive use. When the term “and” as well as “or” are used together, as in “A and / or B” this indicates A or B as well as A and B.
[0020] All ranges and parameters, including but not limited to percentages, parts, and ratios disclosed herein are understood to encompass any and all sub-ranges subsumed therein, andevery number between the endpoints. For example, a stated range of “1 to 10” should be considered to include any and all sub-ranges beginning with a minimum value of 1 or more and ending with a maximum value of 10 or less (e.g., 1 to 6.1 , or 2.3 to 9.4), and to each integer (1 , 2, 3, 4, 5, 6, 7, 8, 9, and 10) contained within the range.
[0021] Any combination of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
[0022] All percentages are percentages by weight unless otherwise indicated.
[0023] Bovine milk contains exosomes which are extracellular bilayer membrane vesicles of approximately 20-200 nm in diameter. These nanosized structures contain several bioactive agents, including, but not limited to, enzymatic and non-enzymatic proteins (e.g., CD9, CD63, MHC-class II, lactadherin, TSG101 and Hsc70, butyrophilin, mucins), nucleic acids (including high amounts of microRNA (miRNA) and messenger RNA (mRNA)) and lipids (e.g., phosphatidylethanolamine, phosphatidylserine, phosphatidylcholine and sphingomyelin). The exosomes account for a minor percentage of milk’s total content.
[0024] The term “an exosome-enriched product” or a “bilayer-enriched product” as used herein, unless otherwise specified, refers to a product comprising bovine milk-derived exosomes in which exosomes have been substantially separated from other bovine milk components such as lipids, cells, and debris, and are concentrated in an amount higher than that found in bovine milk. In specific embodiments, the exosome-enriched product or the bilayer-enriched product is provided in a liquid form or a powdered form and also contains co-isolated milk solids.
[0025] The term “intact exosomes” as used herein, unless otherwise specified, refers to exosomes in which the vesicle membrane is not ruptured and / or otherwise degraded and the endogenous cargo, i.e., bioactive agents, therapeutics (e.g. miRNA), and / or other biomolecules which are inherently present in a bovine milk-derived exosomes, are retained therein in active form. Exosomes are lipid bilayer membrane vesicles that contain different bioactive agents withpowerful health benefits. In order to maintain the internal cargo of exosomes, the exosomes need to remain intact by avoiding overly harsh handling and / or environment.
[0026] Bovine milk exosomes can be isolated from a milk whey fraction or from other dairy streams, such as a cheese whey fraction. They can be isolated by various physical methods (e.g., ultracentrifugation at increasing speeds, membrane ultrafiltration and / or size exclusion chromatography) and / or chemical methods (e.g., the use of polymers to precipitate bovine milk exosomes by an incubation step). Remarkably, most of these procedures tend to co-purify exosomes and other dairy constituents (i.e., caseins and other whey protein). The isolation process yields a fraction enriched in bovine milk exosomes that may then undergo further processing, such as freeze-drying or spray-drying, to produce a powder containing bovine milk exosomes for further applications.
[0027] In a specific embodiment of the invention, the exosome-enriched product comprises at least 0.001 wt % exosomes. In another specific embodiment, the exosome-enriched product comprises at least about 0.001 , 0.01 , 1 , 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 wt % exosomes. In additional specific embodiments of the invention, the exosome-enriched product comprises at least 10 wt % exosomes. In further embodiments, the exosome-enriched product comprises at least about 108exosomes per gram as measured by a nanotracking procedure. Briefly, nanoparticle tracking analysis (NTA) can be used to determine exosome diameter and concentration. The principle of NTA is based on the characteristic movement of nanosized particles in solution according to the Brownian motion. The trajectory of the particles in a defined volume is recorded by a camera that is used to capture the scatter light upon illumination of the particles with a laser. The Stokes-Einstein equation is used to determine the size of each tracked particle. In addition to particle size, this technique also allows determination of particle concentration.
[0028] In a more specific embodiment, the exosome-enriched product employed in the present invention comprises from about 108to about 1014exosomes per gram of the exosome-enriched product. In yet a more specific embodiment, the exosome-enriched product comprises from about 109to about 1013exosomes per gram of the exosome-enriched product. In another specific embodiment, the exosome-enriched product contains at least about a three-fold increase in the number of exosomes, as compared to a raw whey-containing bovine milk fraction. In a more specific embodiment, the exosome-enriched product contains a 3-fold to 50- fold increase in the number of exosomes, as compared to a raw whey-containing bovine milk fraction, for example cheese whey.
[0029] Various forms of vitamin D, a fat-soluble vitamin, exist and are suitable for use in the present invention. In a specific embodiment, the vitamin D comprises vitamin D2, also known as ergocalciferol, and / or vitamin D3, also known as cholecalciferol. Vitamin D2 and D3 can be obtained commercially through different extraction and purification processes.
[0030] Loading efficiency may be used to estimate how effective a loading method is. Loading efficiency or rate may specifically be represented by a percentage calculated from (loaded molecules / input molecules)*100. A low loading efficiency or rate value percentage indicates that most vitamin D molecules are free and not loaded onto exosomes, indicating the loading method is not very effective or efficient.
[0031] The term “light tight environment” as used herein, unless otherwise specified, refers to a space that is otherwise dark, with little to no presence of artificial or natural light.
[0032] The term “nutritional composition” as used herein, unless otherwise specified, refers to nutritional liquids and nutritional powders, the latter of which may be reconstituted or otherwise mixed with a liquid in order to form a nutritional liquid, and are suitable for oral consumption by a human. Nutritional liquids may be prepared in ready-to-drink form or may be reconstituted from powder as described.
[0033] The term “single stirring step” as used herein, unless otherwise specified, refers to a method of loading compounds onto exosomes. This particular loading method, or loading protocol, is considered a passive loading method in that only mixing is done. The mixing maybe accomplished by any means known in the art, such as shaking by vortex. Single stirring step may also be referred to herein as a single step of stirring, mixing, shaking, a strong stir, etc.This passive loading method shall not be construed as limited by any specific mixing method described herein regarding the time, speed, power, etc. used to carry out the single stirring step. In specific embodiments, the single stirring step maintains the intact nature of at least some of the exosomes, and, in more specific embodiments, maintains the intact nature of a majority of the exosomes.
[0034] In one embodiment of the invention, the single stirring step occurs by vortex for about 60 minutes, or about 40-80 minutes, or about 50-70 minutes. In specific embodiments of the invention, the vortex occurs at 500 rpm or more, or about 500-1300 rpm, or about 600-1200 rpm, or about 1000-1200 rpm, or about 1600-1700 rpm, or about 1000-2000 rpm.
[0035] In specific embodiments of the invention, bovine milk exosomes loaded with vitamin D, more specifically vitamin D2 and / or D3, and more particularly, vitamin D3, are provided to a subject, where the subject may be a human adult or pediatric subject.
[0036] The term “pediatric subject” as used herein refers to an infant, child or adolescent up to the age of about 21 years old.
[0037] The term “adult subject” as used herein, refers to an individual at least the age of about 21 years old. In a specific embodiment, the adult subject is an adult at least about 30 years old, or at least about 40 years old, or at least about 50 years old, or at least about 60 years old, or at least about 70 years old, or is about 40-80 years old, or is about 50-70 years old.
[0038] The term “older adult” as used herein, refers to an adult subject at least the age of about 50 years old. In a specific embodiment, the adult subject is an older adult at least about 50 years old, or at least about 60 years old, or at least about 65 years old, or about 50-80 years old, or about 60-70 years old.
[0039] The term “adolescent” as used herein, unless otherwise specified, refers to a pediatric subject at the age of about 10 years to 19 years old, which normally corresponds with the onset of physiologically normal puberty and ends when an adult identity and behavior are accepted.
[0040] In a specific embodiment, the pediatric subject is a child at or under the age of about 18 years old, or at or under the age of about 15 years old, or at or under the age of about 10 years old, or at or under the age of about 5 years old, or at or under the age of about 1 year old, or at or under the age of about 6 months old, or at or under the age of about 3 months old.
[0041] As indicated above, the present invention provides bovine milk exosomes loaded with vitamin D, a nutritional composition that includes vitamin D loaded onto bovine milk exosomes, as well as methods of making the loaded bovine milk exosomes and nutritional composition.
[0042] Without wishing to be bound by any particular theory, the nutritional composition and methods of the present invention promote bioavailability of vitamin D, or, more specifically, vitamin D2 and / or vitamin D3, by loading vitamin D onto bovine milk exosomes. The present inventors have surprisingly discovered that vitamin D can effectively be loaded onto intact bovine milk-derived exosomes.
[0043] In one embodiment, the invention is directed to bovine milk exosomes loaded with vitamin D, comprising at least 0.0001 wt % vitamin D, or at least about 0.0005 wt % vitamin D, or about 0.0001 -0.01 wt % vitamin D, or about 0.0005-0.01 wt % vitamin D, or about 0.001 - 0.002 wt % vitamin D. In another embodiment, the bovine milk exosomes loaded with vitamin D are part of a nutritional composition comprising at least one of a protein, fat and carbohydrate, and the vitamin D-loaded bovine milk exosomes. In specific embodiments of these aspects, the vitamin D is vitamin D2 or vitamin D3.
[0044] In a further embodiment, the invention is directed to a method of preparing a nutritional composition for providing improved bioavailability of vitamin D, or specifically, vitamin D2 and / or vitamin D3 in vivo, comprising adding bovine milk exosomes loaded with vitamin D, or specifically, vitamin D2 and / or vitamin D3 to a nutritional composition.
[0045] In a more specific embodiment, the invention is directed to a method of loading vitamin D, more specifically vitamin D2 or D3, or yet more specifically, vitamin D3, onto bovine milk exosomes to optimize the micellization stage to improve the absorption and bioavailability of D3 to therefore increase the health benefits in a subject. A variety of loading methods may be used to ensure effective binding between vitamin D, more specifically vitamin D2 or D3, or yet more specifically, vitamin D3, and the bovine milk exosomes.
[0046] Loading methods may include, but are not limited to, electroporation, sonication, incubation, freeze-thaw cycles, mixing, and extrusion, among others. The loading efficiency parameters of each loading method depend on the hydrophobicity of a nutrient of interest and the corresponding process. Unfortunately, many of these loading methods present a low loading efficiency.
[0047] In another embodiment, the invention is directed to a method for manufacturing the vitamin D-loaded bovine milk exosomes comprising mixing an aqueous solution of bovine milk exosomes with at least one solubilized vitamin D.
[0048] In a specific embodiment of the invention, mixing is used as a loading method for binding vitamin D onto the bovine milk exosomes as a carrier. In another specific embodiment of the invention, a combination of freeze-thaw cycles are used for loading vitamin D onto the bovine milk exosomes as a carrier. These inventive loading methods avoid rupturing the intact exosomes.
[0049] Fat-soluble vitamins (like vitamin D) are less bioavailable than water-soluble vitamins. While the absorption of fat-soluble vitamins can generally be improved through the use of a lipophilic vehicle, bovine milk exosomes are surprisingly advantageous as a vehicle for vitamin D, specifically, vitamin D2 and / or vitamin D3, and more specifically vitamin D3.
[0050] In another embodiment, the invention is directed to a method for manufacturing the vitamin D-loaded bovine milk exosomes comprising mixing an aqueous solution of bovine milkexosomes with at least one solubilized vitamin D and subjecting the mixture to at least one freezing / thawing cycle.
[0051] The term “freeze / thaw” or “freezing / thawing” as used herein, unless otherwise specified, refers to a method of putting products through at least one cycle of freezing and thawing where a product is first exposed to freezing temperatures for a designated period of time to solidify the product, followed by a thawing step where the product is exposed to a comparatively higher temperature for another designated period of time to return to a liquid state. A series of two, three, four or more freeze / thaw cycles may be employed.
[0052] In embodiments of the invention, freezing occurs at about -25°C, or about -50°C, or about -80°C, or from about -25°C to about -80°C, or from about -60°C to about -90°C.
[0053] In embodiments of the invention, thawing occurs at about 25°C, or about 30°C, or about 35°C, or from about 25 to about 40°C, or from about 30 to about 40°C, or from about 35 to about 40°C.
[0054] In embodiments of the invention, at least one freeze / thaw cycle may be used to load compounds onto exosomes. In a specific embodiment of the invention, vitamin D is loaded onto exosomes by mixing an aqueous solution of bovine milk exosomes with at least one solubilized vitamin D, followed by subjecting the resulting mixture to at least one freeze / thaw cycle. In a further specific embodiment of the invention, bovine milk exosomes are mixed with at least one solubilized vitamin D, followed by two, three or more freeze / thaw cycles.
[0055] In a specific embodiment, at least about 50 wt % of the exosomes are intact. In another specific embodiment, at least about 55, 60, 70, 75, 80, 85, 90, or 95 wt % of the exosomes are intact. The intact exosomes may be loaded or unloaded.
[0056] In a specific embodiment of the invention, an aqueous suspension of bovine milk exosomes is mixed with vitamin D2 and / or D3 dissolved or suspended in a solvent, for example, water and lecithin, to an adequate ratio of exosomes : vitamin D2 and / or D3 using the mixingalone or in combination with freeze / thaw cycle processing described herein. These loading processes have a high efficiency and keep the exosome membrane structures intact.
[0057] In a specific embodiment, the weight ratio of exosomes to vitamin D2 and / or D3 in the resulting mixture is at least about 500:1 . In other specific embodiments, the ratio of exosomes to vitamin D2 and / or D3 in the resulting mixture is at least about 1000:1 , at least about 2000:1 , at least about 4000:1 , at least about 6000:1 , at least about 8000:1 , at least about 10,000:1 , at least about 20,000:1 , at least about 30,000:1 , at least about 40,000:1 , at least about 50,000:1 , at least about 60,000:1 , or at least about 70,000:1 . In a specific embodiment, the weight ratio of exosomes to vitamin D2 and / or D3 in the resulting mixture is about 1000:1 to 60,000:1 , or about 30,000:1 to about 60,000:1 , or 40,000:1 to about 60,000:1 .
[0058] In a specific embodiment of the method of the invention for preparing the loaded exosomes, at least about 15 wt % of the vitamin D, more specifically, vitamin D2 and / or D3, is successfully loaded onto the bovine milk exosomes. In another specific embodiment, at least about 30, 40, 50, 60, 70, 75, or 80 wt % of the vitamin D, more specifically, vitamin D2 and / or D3, is successfully loaded onto the bovine milk exosomes.
[0059] In another specific embodiment of the invention, the bioavailability of vitamin D, or specifically, vitamin D2 and / or vitamin D3, in vivo in a subject is increased upon administration of the vitamin D-loaded bovine milk exosomes to a subject, for example as compared with the administration of vitamin D, or specifically vitamin D2 and / or vitamin D3, in the absence of exosomes.
[0060] In another specific embodiment, the loaded exosomes comprise at least about 0.0001 wt % of vitamin D, or specifically, vitamin D2 and / or vitamin D3. In another specific embodiment, the loaded exosomes comprise at least about 0.0005, 0.0006, 0.0007, 0.0008, 0.0009, or 0.001 wt % of vitamin D, or specifically, vitamin D2 and / or vitamin D3. In yet further specific embodiments, the loaded exosomes comprise from about 0.0001 to about 0.01 wt % vitamin D, or specifically, vitamin D2 and / or vitamin D3, from about 0.0005 to about 0.01 wt %vitamin D, or specifically, vitamin D2 and / or vitamin D3, from about 0.0006 to about 0.01 wt % vitamin D, or specifically, vitamin D2 and / or vitamin D3, from about 0.0005 to about 0.002 wt % vitamin D, or specifically, vitamin D2 and / or vitamin D3, from about 0.0006 to about 0.002 wt % vitamin D, or specifically, vitamin D2 and / or vitamin D3, from about 0.0008 to about 0.003 wt % vitamin D, or specifically, vitamin D2 and / or vitamin D3, or from about 0.001 to about 0.002 wt % vitamin D, or specifically, vitamin D2 and / or vitamin D3.
[0061] In another aspect of the invention, the vitamin D-loaded bovine milk exosomes are included in a nutritional composition. The nutritional composition further includes at least one of protein, fat and carbohydrate. The loaded exosomes may be included in the nutritional composition in an amount sufficient to provide the desired vitamin D content, for example, the recommended daily allowance. For example, the recommend daily allowance (RDA) of vitamin D is 15 micrograms (mcg) of vitamin D for adults. Therefore, in one embodiment, the nutritional composition may contain the loaded exosomes in an amount sufficient to provide at least about 15 micrograms vitamin D per serving, for example, an 8 oz / 237 ml serving. In other specific embodiments, the nutritional composition may comprise about 0.001 to about 30 wt %, about 0.001 to about 10 wt %, about 0.001 to about 5 wt %, about 0.001 to about 1 wt %, about 0.01 to about 10 wt %, about 0.01 to about 5 wt %, about 0.01 to about 1 wt %, about 0.1 to about 10 wt %, about 0.1 to about 5 wt %, about 0.1 to about 1 wt %, about 1 to about 10 wt %, or about 1 to about 5 wt % of the loaded exosomes, based on the weight of the nutritional composition. In a specific embodiment, the nutritional composition comprises from about 0.001 to about 10 wt % of the loaded exosomes, based on the weight of the nutritional composition.
[0062] In another specific embodiment, the nutritional composition comprises carbohydrate. Suitable carbohydrate for inclusion in the nutritional composition comprises fiber, human milk oligosaccharide (HMO), maltodextrin, corn maltodextrin, organic corn, corn syrup, sucralose, cellulose gel, cellulose gum, gellan gum, inositol, carrageenan, fructooligosaccharide, hydrolyzed starch, glucose polymer, corn syrup solid, rice-derived carbohydrate, sucrose,glucose, lactose, honey, sugar alcohol, isomaltulose, sucromalt, pullu Ian , potato starch, galactooligosaccharide, oat fiber, soy fiber, corn fiber, gum arable, sodium carboxymethylcellulose, methylcellulose, guar gum, locust bean gum, konjac flour, hydroxypropyl methylcellulose, tragacanth gum, karaya gum, gum acacia, chitosan, arabinoglactin, glucomannan, xanthan gum, alginate, pectin, low methoxy pectin, high methoxy pectin, cereal beta-glucan, psyllium, inulin, cornstarch, or a combination of two or more thereof.
[0063] The nutritional composition may comprise carbohydrate in an amount from about 5 wt % to about 75 wt % of the nutritional composition. More specifically, the carbohydrate may be present in an amount from about 5 wt % to about 70 wt % of the nutritional composition, including about 5 wt % to about 65 wt %, about 5 wt % to about 50 wt %, about 5 wt % to about 40 wt %, about 5 wt % to about 30 wt %, about 5 wt % to about 25 wt %, about 10 wt % to about 65 wt %, about 20 wt % to about 65 wt %, about 30 wt % to about 65 wt %, about 40 wt % to about 65 wt %, about 40 wt % to about 70 wt %, or about 15 wt % to about 25 wt %, of the nutritional composition.
[0064] In another specific embodiment, the nutritional composition comprises fat. Suitable fat for inclusion in the nutritional composition comprises coconut oil, fractionated coconut oil, soy oil, soy lecithin, corn oil, safflower oil, high oleic sunflower oil, palm olein, canola oil monoglycerides, lecithin, medium chain triglycerides, linoleic acid, alpha-linolenic acid, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, olive oil, high gamma linolenic (GLA) safflower oil, palm oil, palm kernel oil, canola oil, marine oil, fish oil, algal oil, borage oil, cottonseed oil, fungal oil, interesterified oils, transesterified oils, structured lipid, or a combination of two or more thereof.
[0065] The nutritional composition may comprise fat in an amount of from about 0.5 wt % to about 30 wt % of the nutritional composition. More specifically, the fat may be present in an amount from about 0.5 wt % to about 10 wt %, about 1 wt % to about 30 wt % of the nutritional composition, including about 1 wt % to about 20 wt %, about 1 wt % to about 15 wt %, about 1wt % to about 10 wt %, about 1 wt % to about 5 wt %, about 3 wt % to about 30 wt %, about 5 wt % to about 30 wt %, about 5 wt % to about 25 wt %, about 5 wt % to about 20 wt %, about 5 wt % to about 10 wt %, or about 10 wt % to about 20 wt % of the nutritional composition.
[0066] In another specific embodiment, the nutritional composition may comprise protein. Suitable protein for inclusion in the nutritional composition comprises whey protein concentrate, whey protein isolate, whey protein hydrolysate, acid casein, sodium caseinate, calcium caseinate, potassium caseinate, casein hydrolysate, milk protein concentrate, organic milk protein concentrate, milk protein isolate, milk protein hydrolysate, nonfat dry milk, condensed skim milk, soy protein concentrate, isolated soy protein, soy protein hydrolysate, pea protein concentrate, pea protein isolate, pea protein hydrolysate, collagen protein, collagen protein isolate, L-Carnitine, taurine, lutein, rice protein concentrate, rice protein isolate, rice protein hydrolysate, fava bean protein concentrate, fava bean protein isolate, fava bean protein hydrolysate, collagen protein, collagen protein isolate, meat protein, potato protein, chickpea protein, canola protein, mung protein, guinea protein, amaranth protein, chia protein, hemp protein, flax seed protein, earthworm protein, insect protein, one or more amino acids and / or metabolites thereof, or a combination of two or more thereof.
[0067] The one or more amino acids, which may be described as free amino acids, can be any amino acid known for use in nutritional products. The amino acids may be naturally occurring or synthetic amino acids. In a specific embodiment, the one or more amino acids and / or metabolites thereof comprise one or more branched chain amino acids or metabolites thereof. Examples of branched chain amino acids include arginine, glutamine leucine, isoleucine, and valine. In another specific embodiment, the one or more branched chain amino acids or metabolites thereof comprise alpha-hydroxy-isocaproic acid (HICA, also known as leuic acid), keto isocaproate (KIC), p-hydroxy-p-methylbutyrate (HMB), and a combination of two or more thereof.
[0068] The nutritional composition may comprise protein in an amount from about 1 wt % to about 30 wt % of the nutritional composition. More specifically, the protein may be present in an amount from about 1 wt % to about 25 wt % of the nutritional composition, including about 1 wt % to about 20 wt %, about 2 wt % to about 20 wt %, about 1 wt % to about 15 wt %, about 1 wt % to about 10 wt %, about 5 wt % to about 10 wt %, about 10 wt % to about 25 wt %, or about 10 wt % to about 20 wt % of the nutritional composition. Even more specifically, the protein comprises from about 1 wt % to about 5 wt % of the nutritional composition, or from about 20 wt % to about 30 wt % of the nutritional composition.
[0069] The concentration and relative amounts of the sources of protein, carbohydrate, and fat in the exemplary nutritional compositions can vary considerably depending upon, for example, the specific dietary needs of the intended user. In a specific embodiment, the nutritional composition comprises a source of protein in an amount of about 2 wt % to about 20 wt %, a source of carbohydrate in an amount of about 5 wt % to about 30 wt %, and a source of fat in an amount of about 0.5 wt % to about 10 wt %, based on the weight of the nutritional composition, and, more specifically, such composition is in liquid form. In another specific embodiment, the nutritional composition comprises a source of protein in an amount of about 10 wt % to about 25 wt %, a source of carbohydrate in an amount of about 40 wt % to about 70 wt %, and a source of fat in an amount of about 5 wt % to about 20 wt %, based on the weight of the nutritional composition, and, more specifically, such composition is in powder form.
[0070] In one embodiment, the nutritional composition is a liquid nutritional composition and comprises from about 1 to about 15 wt % of protein, from about 0.5 to about 10 wt % fat, and from about 5 to about 30 wt % carbohydrate, based on the weight of the nutritional composition.
[0071] In another embodiment, the nutritional composition is a powder nutritional composition and comprises from about 10 to about 30 wt % of protein, from about 5 to about 15 wt % fat, and from about 30 wt % to about 65 wt % carbohydrate, based on the weight of the nutritional composition.
[0072] In a specific embodiment, the nutritional composition comprises at least one protein comprising milk protein concentrate and / or soy protein isolate, at least one fat comprising canola oil, corn oil, coconut oil and / or marine oil, and at least one carbohydrate comprising maltodextrin, sucrose, and / or short-chain fructooligosaccharide.
[0073] The nutritional composition may also comprise one or more components to modify the physical, chemical, aesthetic, or processing characteristics of the nutritional composition or serve as additional nutritional components. Non-limiting examples of additional components include preservatives, emulsifying agents (e.g., lecithin), buffers, sweeteners including artificial sweeteners (e.g., saccharine, aspartame, acesulfame K, sucralose), colorants, flavorants, thickening agents, stabilizers, and so forth. The nutritional compositions may also include additional vitamins and minerals, for example in amounts complying with the recommended daily allowances.
[0074] In specific embodiments, the nutritional composition has a neutral pH, i.e. , a pH of from about 6 to 8 or, more specifically, from about 6 to 7.5. In more specific embodiments, the nutritional composition has a pH of from about 6.5 to 7.2 or, more specifically, from about 6.8 to 7.1.
[0075] The nutritional composition may be formed using any techniques known in the art. In one embodiment, the nutritional composition may be formed by (a) preparing an aqueous solution comprising protein and carbohydrate; (b) preparing an oil blend comprising fat and oilsoluble components; and (c) mixing together the aqueous solution and the oil blend to form an emulsified liquid nutritional composition. The loaded exosomes may be added at any time as desired in the process, for example, to the aqueous solution or to the emulsified blend. The loaded exosomes may be dry blended in powder form with one or more dry ingredients, for example, for combined addition to a liquid composition or if a powdered nutritional product is desirable.
[0076] In a specific embodiment, the nutritional composition is administered in the form of a powder. In another specific embodiment, the nutritional composition is administered in the form of a liquid. The nutritional composition can be administered to the subject in either form. When the nutritional composition is a powder, for example, a serving size is from about 40 g to about 60 g, such as 45 g, or 48.6 g, or 50 g, to be administered as a powder or to be reconstituted in from about 1 ml to about 500 ml of liquid.
[0077] When the nutritional composition is in the form of a liquid, for example, reconstituted from a powder or manufactured as a ready-to-drink product, a serving ranges from about 1 ml to about 500 ml, including from about 110 ml to about 500 ml, from about 110 ml to about 417 ml, from about 120 ml to about 500 ml, from about 120 ml to about 417 ml, from about 177 ml to about 417 ml, from about 207 ml to about 296 ml, from about 230 m to about 245 ml, from about 110 ml to about 237 ml, from about 120 ml to about 245 ml, from about 110 ml to about 150 ml, and from about 120 ml to about 150 ml. In specific embodiments, the serving is about 1 ml, or about 100 ml, or about 225 ml, or about 237 ml, or about 500 ml.
[0078] In specific embodiments, the nutritional compositions comprising the vitamin D-loaded bovine milk exosomes are administered to a subject once or multiple times daily or weekly. In specific embodiments, the nutritional composition is administered to the subject from about 1 to about 6 times per day or per week, or from about 1 to about 5 times per day or per week, or from about 1 to about 4 times per day or per week, or from about 1 to about 3 times per day or per week. In specific embodiments, the nutritional composition is administered once or twice daily for a period of at least one week, at least two weeks, at least three weeks, or at least four weeks.
[0079] The following Examples demonstrate various embodiments of the invention.EXAMPLES
[0080] Example 1 : Method for Preparing an Exosome-Enriched Product
[0081] This example describes a method of preparing an exosome-enriched product from cheese whey. The cheese whey was provided by adding rennet enzyme to bovine milk, resulting in enzymatic coagulation of casein and production of sweet cheese whey.
[0082] An exosome-enriched product containing from about 108to about 1014intact bovine milk-derived exosomes per gram of the exosome-enriched product was prepared by cascade membrane filtration. First, 1 ,000 L of the sweet cheese whey was processed using tandem multiple ceramic filtration steps. The first microfiltration (MF) step employed a membrane with a molecular weight cut off of 1 .4 pm, which yielded a first retentate R1 and a first permeate P1 . The first permeate P1 was then subjected to an ultrafiltration step (UF) with a molecular weight cut off of 0.14 pm, which yielded a second retentate R2 and a second permeate P2. About 5 volumes of water was added to one volume of the second retentate R2, and the diluted retentate was then passed through the 0.14 pm LIF membrane again to remove at least part of the lactose and minerals. The resulting retentate R3 was then mixed with an equal volume of water and diafiltered using a 10 kDa membrane to produce a fourth retentate R4. The retentate R4 was diluted with a volume of water five times that of the fourth retentate R4 and diafiltered a second time using the 10 kDa membrane to yield a concentrated retentate, R5. The lactose-free exosome-enriched product R5 was pasteurized at 70°C for 15 seconds to ensure microbiological stability in order to yield a pasteurized exosome-enriched product R6. The pasteurized exosome-enriched product R6 was subjected to evaporation at about 65°C to increase the solids content up to 17-18% and then spray-dried at 185°C / 85°C to obtain an exosome-enriched spray-dried product.
[0083] Example 2: Mixing Method for Loading Vitamin D3 onto Bovine Milk Exosomes
[0084] This example describes a method of preparing vitamin D3-loaded bovine milk exosomes. The exosomes were spray-dried bovine milk-enriched exosomes prepared according to the method described in Example 1 .
[0085] Sample 1 was prepared by first suspending 3 g of spray-dried bovine milk exosomes from Example 1 in 100 ml of ultrapure water with lecithin at a concentration of 0.05 mg / ml.Vitamin D3 was dissolved in ethanol at a concentration of 20 gg / ml. To develop a bioactive complex, 82.5 ml of the exosome suspension was mixed with 2.5 ml of the vitamin D3 solution to form a mixture with an exosome to vitamin D3 weight ratio of about 50,000:1 . The solutions were mixed by a single stirring step by vortex for 60 minutes at 1600-1700 rpm.
[0086] Sample 2 was prepared using the same conditions as Sample 1 , but without exosomes. Specifically, vitamin D3 was dissolved in ethanol at a concentration of 20 pg / ml. A solution of ultrapure water was prepared with 0.05 mg / ml of lecithin. 2.5 ml of the vitamin D3 suspension was mixed with 82.5 ml of the water and lecithin solution. The solutions were mixed by a single stirring step by vortex for 60 minutes at 1600-1700 rpm. This was done to provide information about what would happen to the vitamin D3 when there are no exosomes present.
[0087] The preparations of Samples 1 and 2 were performed in a room temperature environment at 25°C and in darkness, in a light tight environment, to avoid light-degradation of the solutions.
[0088] Example 3: Freeze and Thaw Method for Loading Vitamin D3 onto Bovine Milk Exosomes
[0089] This example describes a method of preparing vitamin D3-loaded bovine milk exosomes. The exosomes were spray-dried bovine milk-enriched exosomes prepared according to the method described in Example 1 .
[0090] Sample 3 was prepared by first suspending 3 g of spray-dried bovine milk exosomes from Example 1 in 100 ml of ultrapure water with lecithin at a concentration of 0.05 mg / ml.Vitamin D3 was dissolved in ethanol at a concentration of 20 gg / ml. To develop a bioactive complex, 82.5 ml of the exosome suspension was mixed with 2.5 ml of the vitamin D3 solution to form a mixture with an exosome to vitamin D3 weight ratio of about 50,000:1 . The solutions were mixed by a single stirring step by vortex for 60 minutes at 1600-1700 rpm. The bovine milkexosomes and vitamin D3 mixture was subjected to three freeze / thaw cycles of freezing at -80°C, followed by thawing at 37°C.
[0091] Sample 4 was prepared by first suspending 3 g of spray-dried bovine milk exosomes from Example 1 in 100 ml of ultrapure water (this time with no lecithin). Vitamin D3 was dissolved in ethanol at a concentration of 20 pg / ml. The exosome suspension and vitamin D3 suspension were mixed together by a single stirring step by vortex for 60 minutes at 1600-1700 rpm to form a mixture with an exosome to vitamin D3 ratio of about 50,000:1 . The bovine milk exosomes and vitamin D3 mixture was subjected to three freeze / thaw cycles of freezing at - 80°C, followed by thawing at 37°C.
[0092] Example 4: Calculating Efficiency of the Loading Process
[0093] To determine free vitamin D3 content, Samples 1 -4 from Examples 2 and 3 were each centrifuged at 36,000 g for 90 minutes at 4°C to separate supernatant from pellet. Centrifugation was performed to accelerate the precipitation of a portion of the vitamin D3 that was not solubilized in the aqueous medium. Due to their weight, it was known that the exosomes would remain in the supernatant at the selected centrifugation speed. Thereafter, loading efficiency of vitamin D3 on exosomes was calculated by determining the concentration of free vitamin D3 in supernatant and in the pellet.
[0094] By quantifying the free vitamin D3 both in the supernatant and in the pellet, the amount of vitamin D3 that has been bound to the exosomes can be determined. The quantity of vitamin D3 measured corresponds to the free vitamin D3 (not bound to exosomes). Therefore the remaining amount of vitamin D3 that is not detected in its free form in either the pellet or supernatant is bound to the exosomes.
[0095] As such, both the supernatant and pellet fractions of each sample were analyzed to check for free vitamin D3. A mass spectrometry detector can analyze the exact molecular weight of vitamin D3. Vitamin D3 was analyzed by UHPLC-MS / MS using a chromatographic column, Acquity UPLC BEH C18, 1 .7 pm, 2.1x100 mm at 30°C, and with a mobile phase ofethanol at a flow of 0.3 ml / min with an injection volume of 2 pl and a run time of 2.5 minutes. This resulted in an analysis of free vitamin D3 both in pellet and in supernatant. The loading efficiency was then calculated using the following equation with the mass spectrometry data:Efficiency of loading (%) = 100% - (% Free Vitamin D3 + % Free Vitamin D3) in supernatant in pellet
[0096] Analyzing Samples 1 and 2 from Example 2, Sample 1 achieved a loading efficiency of about 81%. Because all of the vitamin D3 was present in free form in Sample 2, Sample 2 demonstrates that the vitamin D3 that was not present in free form in either the supernatant or the pellet was loaded onto the exosomes in Sample 1 . Analyzing Samples 3 and 4 from Example 3, Sample 3 achieved a loading efficiency of about 72%, while Sample 4 achieved a loading efficiency of about 53%.
[0097] The high loading efficiency values of Samples 1 and 3 were surprising and unexpected, especially in comparison to other loading methods and medium. Specifically, Samples 1 and 3, with water and lecithin, provided much higher loading efficiencies than with the loading method using water only in Sample 4. These comparison loading efficiencies are shown in Table 1 below.Table 1 : Efficiency of loading protocols in different mediums of vitamin D3
[0098] Mixing exosomes and vitamin D3 at a ratio of 50,000:1 using three freezing / thawing cycles with water and ethanol was employed and the loading efficiency was determined to be 53% (Sample 4). Mixing exosomes and vitamin D3 (in ethanol) at a weight ratio of exosomes to vitamin D3 of 50,000:1 for 1 hour in water and lecithin as described in Example 2 resulted in a loading efficiency of 81% (Sample 1 ). Mixing exosomes and vitamin D3 (in ethanol) at a weight ratio of exosomes to vitamin D3 of 50,000:1 , followed by three freeze-thaw cycles with water and lecithin as in Example 3 resulted in a loading efficiency of 72% (Sample 3). Therefore, using water alone as a loading medium did not provide desirably high loading efficiencies for either the mixing or freeze / thaw protocols. However, the exosome solutions with water and lecithin provided desirably high loading efficiencies onto exosomes for both the mixing and freeze / thaw protocols.
[0099] The significant improvements in loading efficiency obtained through the inclusion of an emulsifier, here lecithin, was unexpected because it was understood that the inclusion of the lecithin could pose a risk of breaking the lipophilic bilayer of the exosome. As such, the emulsifier, here lecithin, was included in very low quantities. It is believed that the inclusion of high amounts of an emulsifier such as lecithin may break the lipophilic bilayer of the exosome and thus produce low, or even zero, loading of vitamin D.
[0100] Further, the high loading efficiency obtained was a surprising and unexpected result given the passive loading method that was used. Traditionally, the main drawback to passive loading methods is low loading efficiency. Thus, the ability to achieve a loading efficiency of greater than 50%, indeed of 70% or greater or even 80% or greater, was highly unexpected.
[0101] The high loading efficiency produced samples in which the loaded exosomes comprise greater than 0.001 wt % vitamin D3. For instance, the samples were each mixed at aweight ratio of exosomes to vitamin D3 of 50,000:1 , which equates to 0.002 wt % vitamin D3. A loading efficiency of 53%, such as was obtained in Sample 4, therefore produces a sample in which the loaded exosomes comprise about 0.001 wt %. The higher loading efficiencies achieved in Samples 3 and 4 produced samples in which the loaded exosomes comprised about 0.0014 wt % and about 0.0016 wt %, respectively.
[0102] The loading of vitamin D, more specifically vitamin D2 and / or D3, and more specifically vitamin D3, onto exosomes is believed to enhance the bioavailability of the vitamin D. For example, animal studies done with vitamin K2 (another fat soluble vitamin) demonstrate that an improved absorption and bioavailability of vitamin K2 was obtained when the vitamin was associated with bovine milk exosomes in comparison to when the vitamin was administered alone. This study is described in PCT / US2023 / 027488 at Example 5, which is incorporated by reference herein. Although the effects on absorption and bioavailability achieved by the loading of exosomes with vitamin D in particular were not tested, one would predict a similar improvement in vitamin D bioavailability to those observed with vitamin K2.
[0103] In summary, the present invention provides loaded exosomes and nutritional compositions with a desirable quantity of vitamin D, more specifically, vitamin D2 and / or D3, and more specifically, vitamin D3, that is achieved by the methods presented herein of loading vitamin D, more specifically, vitamin D2 and / or D3, and more specifically, vitamin D3, onto bovine milk exosomes. Such compositions and methods are useful for efficient and / or for large- scale production of various nutritional compositions, especially for individuals deficient in, or in otherwise need of, increased vitamin D absorption or bioavailability.
[0104] The specific embodiments and examples described herein are exemplary only and are not limiting to the invention defined in the claims. Additionally, while the present invention has been illustrated by the description of embodiments thereof, and while the embodiments have been described in considerable detail, such descriptions are not intended to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages andmodifications will readily appear to those skilled in the art. Therefore, the invention, in its broader aspects, is not limited to the specific details, the representative compositions and processes, or illustrative examples shown and described. Accordingly, departures may be made from such details without departing from the spirit or scope of the general inventive concept.
Claims
ClaimsWhat is claimed is:1 . Bovine milk exosomes loaded with vitamin D.
2. The bovine milk exosomes loaded with vitamin D of claim 1 , wherein vitamin D comprises vitamin D2 and / or vitamin D3.
3. The bovine milk exosomes loaded with vitamin D of claim 1 , wherein vitamin D comprises at least vitamin D3.
4. The bovine milk exosomes loaded with vitamin D of any one of claims 1 -3, comprising at least 0.0001 wt % vitamin D3, or from about 0.0001 to about 0.01 wt % vitamin D3; optionally comprising at least 0.001 wt % vitamin D3, or from about 0.001 wt % to about 0.002 wt % vitamin D3.
5. The bovine milk exosomes loaded with vitamin D of any one of claims 1 -4, wherein the bovine milk exosomes comprise intact exosomes.
6. A nutritional composition comprising at least one of protein, fat and carbohydrate, and optionally all three, and further comprising the vitamin D-loaded bovine milk exosomes of claim 1 .
7. The nutritional composition of claim 6, wherein the vitamin D-loaded bovine milk exosomes comprise at least about 0.0005 wt % vitamin D3, optionally at least about0.001 wt % vitamin D3, optionally about 0.0005 to about 0.01 wt %, optionally about0.001 wt % to about 0.002 wt %.
8. The nutritional composition of claim 6 or 7, wherein the nutritional composition comprises at least about 0.001 to about 10 wt % of the vitamin D-loaded bovine milk exosomes.
9. The nutritional composition of any one of claims 6-8, wherein the nutritional composition comprises one or more proteins comprising whey protein concentrate, whey protein isolate, whey protein hydrolysate, acid casein, sodium caseinate, calcium caseinate, potassium caseinate, casein hydrolysate, milk protein concentrate, organic milk protein concentrate, milk protein isolate, milk protein hydrolysate, nonfat dry milk, condensed skim milk, soy protein concentrate, isolated soy protein, soy protein hydrolysate, pea protein concentrate, pea protein isolate, pea protein hydrolysate, collagen protein, collagen protein isolate, L-Carnitine, taurine, lutein, rice protein concentrate, rice protein isolate, rice protein hydrolysate, fava bean protein concentrate, fava bean protein isolate, fava bean protein hydrolysate, collagen protein, collagen protein isolate, meat protein, potato protein, chickpea protein, canola protein, mung protein, guinea protein, amaranth protein, chia protein, hemp protein, flax seed protein, earthworm protein, insect protein, one or more amino acids and / or metabolites thereof, or a combination of two or more thereof.
10. The nutritional composition of any one of claims 6-9, wherein the nutritional composition comprises one or more fats comprising coconut oil, fractionated coconut oil, soy oil, soy lecithin, corn oil, safflower oil, high oleic sunflower oil, palm olein, canola oil monoglycerides, lecithin, medium chain triglycerides, linoleic acid, alpha-linolenic acid,arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, olive oil, high gamma linolenic (GLA) safflower oil, palm oil, palm kernel oil, canola oil, marine oil, fish oil, algal oil, borage oil, cottonseed oil, fungal oil, interesterified oils, transesterified oils, structured lipid, or a combination of two or more thereof.11 . The nutritional composition of any one of claims 6-10, wherein the nutritional composition comprises one or more carbohydrates comprising fiber, human milk oligosaccharide (HMO), maltodextrin, corn maltodextrin, organic corn, corn syrup, sucralose, cellulose gel, cellulose gum, gellan gum, inositol, carrageenan, fructooligosaccharide, hydrolyzed starch, glucose polymer, corn syrup solid, rice-derived carbohydrate, sucrose, glucose, lactose, honey, sugar alcohol, isomaltulose, sucromalt, pullulan, potato starch, galactooligosaccharide, oat fiber, soy fiber, corn fiber, gum arable, sodium carboxymethylcellulose, methylcellulose, guar gum, locust bean gum, konjac flour, hydroxypropyl methylcellulose, tragacanth gum, karaya gum, gum acacia, chitosan, arabinoglactin, glucomannan, xanthan gum, alginate, pectin, low methoxy pectin, high methoxy pectin, cereal beta-glucan, psyllium, inulin, cornstarch, or a combination of two or more thereof.
12. The nutritional composition of any one of claims 6-11 , wherein the nutritional composition comprises a source of protein in an amount of about 2 wt % to about 20 wt %, a source of carbohydrate in an amount of about 5 wt % to about 30 wt %, and a source of fat in an amount of about 0.5 wt % to about 10 wt %, based on the weight of the nutritional composition, and the nutritional composition is in liquid form, or comprises a source of protein in an amount of about 10 wt % to about 25 wt %, a source of carbohydrate in an amount of about 40 wt % to about 70 wt %, and a source of fat in anamount of about 5 wt % to about 20 wt %, based on the weight of the nutritional composition, and the nutritional composition is in powder form.
13. A method for manufacturing the vitamin D-loaded bovine milk exosomes of claim 1 , comprising mixing an aqueous solution of bovine milk exosomes with at least one solubilized vitamin D.
14. The method of claim 13, wherein the solubilized vitamin D comprises vitamin D3.
15. The method of claim 14, further comprising including an emulsifier, optionally wherein the emulsifier is lecithin, in at least one of the aqueous solution of bovine milk exosomes and the solubilized vitamin D.
16. The method of any one of claims 13-15, wherein powdered bovine milk exosomes are suspended in water to form the aqueous solution.
17. The method of any one of claims 14-16, wherein the mixture comprises an exosome to vitamin D3 weight ratio of at least about 40:1 .
18. The method of any one of claims 14-17, wherein the mixture comprises an exosome to vitamin D3 weight ratio of at least about 1000:1 , 10,000:1 , 30,000:1 , 40,000:1 , or 50,000:1.
19. The method of any one of claims 14-18, wherein the mixture comprises an exosome to vitamin D3 weight ratio of about 1000:1 to about 60,000:1 .
20. The method of any one of claims 14-19, wherein at least about 15 wt %, 30 wt %, 40 wt %, 50 wt %, 60 wt %, or 70 wt % of the vitamin D3 in the mixture is loaded onto the exosomes.21 . The method of any one of claims 14-20, wherein at least about 75 wt % of the vitamin D3 in the mixture is loaded onto the exosomes.
22. A method for manufacturing the vitamin D-loaded bovine milk exosomes of claim 1 , comprising mixing an aqueous solution of bovine milk exosomes with at least one solubilized vitamin D and subjecting a resulting mixture to at least one freezing / thawing cycle.
23. A method of preparing a nutritional composition for providing improved bioavailability of vitamin D, or specifically vitamin D2 and / or vitamin D3, in vivo, comprising adding bovine milk exosomes loaded with vitamin D, or specifically vitamin D2 and / or vitamin D3, to a nutritional composition, wherein the nutritional composition comprises at least one of protein, fat and carbohydrate.
24. A method of enhancing vitamin D, or specifically vitamin D2 and / or vitamin D3, bioavailability in a human subject, comprising administering the vitamin D-loaded bovine milk exosomes or the nutritional composition comprising vitamin D-loaded bovine milk exosomes of any one of claims 1 to 12 to the human subject.
25. A method of providing vitamin D in a bioavailable form to a human subject, comprising administering the vitamin D-loaded bovine milk exosomes or the nutritional compositioncomprising vitamin D-loaded bovine milk exosomes of any one of claims 1 to 12 to the human subject.
Citation Information
Patent Citations
Bovine milk-isolated powdered exosomes, nutritional compositions and methods
US20220395535A1
Cited By
A method of preparing a dry powder of milk extracellular vesicles (MEVS) and MEV dry powder obtained thereof
WO2026133267A1
